Skip to main content
OpenTrials
Completed

NCT Number: NCT06208592

Comparative Study of Anaconda System Use Versus Conventional Sedation in COVID-19 Patients.

At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Acute Kidney Injury Coronaviridae Infections Coronavirus Infections Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Infections Kidney Diseases Lung Diseases Male Urogenital Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Renal Insufficiency Respiration Disorders Respiratory Failure Respiratory Insufficiency Respiratory Tract Diseases Respiratory Tract Infections Urogenital Diseases Urologic Diseases Virus Diseases

Age range

27 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital H+ Queretaro

Querétaro City, Querétaro, 76000, Mexico

About this study

Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with confirmed COVI-19 infection and assited with mechanical ventilation who entered critical care department.

Exclusion criteria

  • Tranfers to a different hospital.
  • Death within the first 24 hours of hospital stay.

Treatment and study plan

Sevoflurane with AnaConDa

Device

Sevoflurane administered with AnaConDa device

Primary outcomes

  1. Intravenous sedation requirements

    Time frame: 7 days

    Amount of intravenous sedation required

Secondary outcomes

  1. Delirium

    Time frame: Hospital stay (up to 30 days)

    Number of patients that suffered delirium

  2. Acute kidney injury

    Time frame: Hospital stay (up to 30 days)

    Number of patients that suffered delirium

  3. VAP

    Time frame: Hospital stay (up to 30 days)

    Number of patients that suffered ventilation acquired pneumonia

Sponsors and collaborators

Lead sponsor

Hospital Español de Mexico

Other

Collaborators

  • Universidad Nacional Autonoma de Mexico

Registry information

Official study title

Comparative Study of Sedative Requirement Using Sevoflurane With Anaconda Device Versus Conventional Sedation in Patients With COVID-19

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 17, 2024
Registry last updated
Jan 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.